Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 748 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peptide vaccine Clear all
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
CMVpp65-A*0201 peptide vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2009 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003222
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 1, 2026, 1:32 PM EDT
Active, not recruiting Phase 1 Interventional

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

NCT03299309
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma
Interventions
PEP-CMV
Drug
Lead sponsor
Daniel Landi
Other
Eligibility
3 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

NCT03391232
View directory record Official record
Conditions
Colorectal Cancer
Interventions
PolyPEPI1018 CRC Vaccine
Biological
Lead sponsor
Treos Bio Zrt
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

NCT00450463
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

NCT00090493
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 1, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

NCT05013216
View directory record Official record
Conditions
High Risk Cancer, Pancreatic Cancer
Interventions
Cohort A: Patients at high risk of developing pancreatic cancer., Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Results available

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

NCT02193347
View directory record Official record
Conditions
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
Biological · Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 1, 2026, 1:32 PM EDT
Not listed Phase 1 Interventional

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

NCT00532974
View directory record Official record
Conditions
HIV Infections
Interventions
EP1090
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
West Hollywood, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT02465268
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions
pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 1, 2026, 1:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions
ELI-002 7P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
Drug
Lead sponsor
Seattle Project Corporation
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 1, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

NCT00972309
View directory record Official record
Conditions
Prostate Specific Antigens, Prostate Neoplasms
Interventions
T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 1, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

UMD rPA Regimen Trial in Adults

NCT00133484
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

NCT02737787
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
Interventions
WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

NCT00014573
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 1, 2026, 1:32 PM EDT
Recruiting Phase 1 Interventional

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326
View directory record Official record
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

NCT05279365
View directory record Official record
Conditions
SARS CoV 2 Infection, COVID-19
Interventions
Pfizer/BioNTech (BNT162b2), Moderna
Biological
Lead sponsor
DHR Health Institute for Research and Development
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 1, 2026, 1:32 PM EDT
Suspended Phase 1Phase 2 Interventional

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

NCT06639607
View directory record Official record
Conditions
Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
Interventions
PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 25 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2051
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

NCT00001060
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 C4-V3 Polyvalent Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 1, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

NCT00948480
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Autologous tumor cells plus dendritic cells, GM-CSF
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 1, 2026, 1:32 PM EDT